This company listing is no longer active
IBXDA Stock Overview
Provides medical imaging technologies using magnetic resonance.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Imagion Biosystems Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.32 |
| 52 Week High | AU$0.36 |
| 52 Week Low | AU$0.30 |
| Beta | 2.32 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBXDA | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 1.6% | -2.8% | -0.5% |
| 1Y | n/a | 21.4% | 7.2% |
Return vs Industry: Insufficient data to determine how IBXDA performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how IBXDA performed against the Australian Market.
Price Volatility
| IBXDA volatility | |
|---|---|
| IBXDA Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: IBXDA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IBXDA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Isaac Bright | imagionbiosystems.com |
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer.
Imagion Biosystems Limited Fundamentals Summary
| IBXDA fundamental statistics | |
|---|---|
| Market cap | AU$10.94m |
| Earnings (TTM) | -AU$11.73m |
| Revenue (TTM) | AU$3.50m |
3.0x
P/S Ratio-0.9x
P/E RatioIs IBXDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBXDA income statement (TTM) | |
|---|---|
| Revenue | AU$3.50m |
| Cost of Revenue | AU$4.05m |
| Gross Profit | -AU$557.56k |
| Other Expenses | AU$11.17m |
| Earnings | -AU$11.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -15.95% |
| Net Profit Margin | -335.61% |
| Debt/Equity Ratio | -92.5% |
How did IBXDA perform over the long term?
See historical performance and comparison